India, Nov. 18 -- Biocon Limited (BIOCON) announced that the European Commission has granted marketing authorization for Pebrilzo, its pertuzumab biosimilar, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU).

Pebrilzo is the first biosimilar to receive European Commission marketing authorization under the European Medicines Agency's (EMA) new tailored clinical approach.

The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026, and comes after the recent U.S. FDA approval of Biocon's pertuzumab biosimilar.

Pertuzumab is a monoclonal antibody that targets the HER2 protein, which is found in higher amounts in certain ...